Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases

Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Sep 30, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called amino acid PET/MRI to better understand and diagnose brain tumors, specifically gliomas and brain metastases. While MRI is commonly used to spot brain tumors, it sometimes struggles to accurately determine the tumor’s grade or to tell the difference between active tumor tissue and changes caused by previous treatments. The researchers believe that combining PET scans with MRI could provide clearer images and more accurate information about the tumors. They will evaluate three promising PET tracers to see which one works best for diagnosing and planning treatment for these conditions.

Adults aged 18 and older who are scheduled for treatment of specific types of gliomas or brain metastases may be eligible to participate. Key requirements include having a planned tissue sample taken for diagnosis and being able to care for themselves. Participants can expect to undergo imaging tests that will help doctors better understand their condition and plan appropriate treatments. It’s also important to note that individuals with certain medical devices, those who cannot give consent, pregnant or breastfeeding women, and those weighing over 120 kg may not qualify for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Inclusion criteria Glioma (LGG, HGG and recurrent HGG):
• • Planned treatment for WHO grade II-IV diffuse glioma
• • Adult patients (\>18 years)
• • Planned tissue sampling for histopathological diagnosis.
• • KPS \>60 (able to care for self)
• Inclusion criteria Brain Metastasis:
• • Indication of surgery or stereotactic radiosurgery for 1-4 brain metastases
• • Planned surgery: Suspicion of brain metastasis or known diagnosis
• • Stereotactic surgery: Known primary cancer
• • Adult patients (\>18 years)
• • Estimated survival at least 3 months after inclusion
• Exclusion Criteria:
• * Exclusion criteria (Glioma and Brain Metastasis):
• • Pacemakers or defibrillators not compatible with 3T MRI
• • No ability to obtain informed consent (e.g. due to severe dysphasia or cognitive deficits).
• • Pregnancy (pregnancy test for all women in fertile age when doubt about possible pregnancy exist)
• • Breastfeeding
• • Weight \> 120 kg